Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CSL Behring
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) \[1987\] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[2010\]) at least 16 weeks prior to screening
ACR global functional status class of 1 to 3
Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors
All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening
Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1)
Elevated High-sensitivity (hs) CRP and/or ESR
You may not be if
Active serious infection
History of or active tuberculosis (TB)
Elevated liver function tests (LFTs)
Clareo Health | Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
